NEJM at ESMO — Phase 3 Trial of Cabozantinib in Advanced Neuroendocrine Tumors

Date:

In this audio interview, Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research being presented at the 2024 European Society of Medical Oncology annual meeting. . . .

​   The New England Journal of Medicine: Search Results in Hematology/Oncology

Share post:

Subscribe

spot_imgspot_img

Popular

More like this
Related

Temu vende copias de marcas noruegas: – No tienen derecho

NRK No tienen derecho a hacer esto. Es un claro...

Protests live updates: Multiple arrests in NYC as LA enters 6th night of protests

ABC ByJack Moore, Riley Hoffman, Kevin Shalvey, Leah Sarnoff, and...

La administración Trump elimina la sección «Seguridad» del Instituto de Seguridad de IA

NBC Por Bruna Horvath La administración Trump dice que está reformando un...